Bibek Aryal, Surgeon-Scientist, Independent Researcher in Cancer Outcomes, shared a post on X:
“Our new Comment in NatureRevClinOncol asks:
When evidence is credible and a treatment is generic, who owns the development pathway?
Often, no one. That is the gap open-source oncology is designed to fill.”
Title: Patient value over patent value: the mandate for open-source oncology
Authors: Bibek Aryal, Dario Trapani
Read the Full Article.
Other articles featuring Bibek Aryal and Dario Trapani on OncoDaily.